Accounting for established risk factors for CKD, the relative rate of progressive kidney dysfunction was higher than in matched controls for patients treated with CDK4/6 inhibitors (HR, 1.9; 95% CI, 1.4-2.6), EGFR inhibitors (HR, 1.8; 95% CI, 1.2-2.5), VEGFR inhibitors (HR, 2.1; 95% CI, 1.6-2.7), B-Raf (BRAF) inhibitors (HR, 1.9; 95% CI, 1.1-3.3), and MET inhibitors (HR, 5.3; 95% CI, 1.9-14.5) (Table 2). Here, MET is linked to chronic kidney disease.